← Back to Search

ADAMM- RSM Device for Cystic Fibrosis

N/A
Waitlist Available
Led By Giovanni Ferrara, MD
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 month duration per participant
Awards & highlights

Study Summary

This trial will test a new device that monitors heart rate, breathing rate, temperature, cough, and activity to see if it can predict worsening or increasing severity of lung conditions.

Eligible Conditions
  • Cystic Fibrosis
  • Tuberculosis
  • Idiopathic Pulmonary Fibrosis
  • Lung Transplant
  • Bronchiectasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 month duration per participant
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 month duration per participant for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Length of time wearing device (days)
Secondary outcome measures
Prediction of respiratory exacerbations- Number of emergency room visits
Prediction of respiratory exacerbations- Number of hospital admissions

Trial Design

1Treatment groups
Experimental Treatment
Group I: DeviceExperimental Treatment1 Intervention
All participants will wear the device to assist in determining the feasibility of wearing the device.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ADAMM- RSM Device
2021
N/A
~10

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor
897 Previous Clinical Trials
387,199 Total Patients Enrolled
1 Trials studying Cystic Fibrosis
213 Patients Enrolled for Cystic Fibrosis
Giovanni Ferrara, MDPrincipal InvestigatorUniversity of Alberta
1 Previous Clinical Trials
40 Total Patients Enrolled
~2 spots leftby May 2025